178 related articles for article (PubMed ID: 22659960)
21. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
[TBL] [Abstract][Full Text] [Related]
22. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
23. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
24. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Dang J; Li G; Zang S; Zhang S; Yao L
Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
[TBL] [Abstract][Full Text] [Related]
25. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
26. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Oh IJ; Kim KS; Kim YC; Ban HJ; Kwon YS; Kim YI; Lim SC; Chung WK; Nam TK; Song JY; Yoon MS; Ahn SJ
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1247-54. PubMed ID: 24091849
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).
Schild SE; Hillman SL; Tan AD; Ross HJ; McGinnis WL; Garces YA; Graham DL; Adjei AA; Jett JR;
J Thorac Oncol; 2017 Apr; 12(4):697-703. PubMed ID: 28089762
[TBL] [Abstract][Full Text] [Related]
28. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
Wozniak AJ; Moon J; Thomas CR; Kelly K; Mack PC; Gaspar LE; Raben D; Fitzgerald TJ; Pandya KJ; Gandara DR
Clin Lung Cancer; 2015 Sep; 16(5):340-7. PubMed ID: 25703100
[TBL] [Abstract][Full Text] [Related]
29. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.
Sun Y; Duan Q; Chen X; Chen W; Jin X; Wu R
Clin Transl Oncol; 2017 Dec; 19(12):1498-1506. PubMed ID: 28589432
[TBL] [Abstract][Full Text] [Related]
31. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR
Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721
[TBL] [Abstract][Full Text] [Related]
32. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
[TBL] [Abstract][Full Text] [Related]
33. Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer.
Johnson MD; Sura K; Mangona VS; Glick A; Wallace M; Ye H; Grills IS
Clin Lung Cancer; 2017 Mar; 18(2):149-155. PubMed ID: 27426973
[TBL] [Abstract][Full Text] [Related]
34. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
35. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity.
Phernambucq ECJ; Spoelstra FOB; Verbakel WFAR; Postmus PE; Melissant CF; Maassen van den Brink KI; Frings V; van de Ven PM; Smit EF; Senan S
Ann Oncol; 2011 Jan; 22(1):132-138. PubMed ID: 20595452
[TBL] [Abstract][Full Text] [Related]
38. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer.
Guilbault C; Garant A; Faria S; Owen S; Ofiara L; Duclos M; Hirsh V; Kopek N
Clin Lung Cancer; 2017 Sep; 18(5):565-571. PubMed ID: 28344046
[TBL] [Abstract][Full Text] [Related]
39. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
[TBL] [Abstract][Full Text] [Related]
40. Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Tagawa T; Iwata T; Nakajima T; Suzuki H; Yoshida S; Yoshino I
World J Surg; 2016 Apr; 40(4):906-12. PubMed ID: 26711642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]